Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) Stock Ticker

NASDAQ: GILD · Healthcare · Drug Manufacturers - General
$152.21+0.83%
USD · as of 2026-09-29 · market cap $187.1B
Open GILD in TickrDownload for iPhone

GILD right now

Options expect by Oct 6±4.2%
Options expect by Oct 29±8.6%
Priced in for Oct 29 earnings±8.6%
IV rank (30-day)52% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full GILD picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on GILD
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

GILD stock facts

Ticker symbolGILD
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryDrug Manufacturers - General
Market cap$187.1B
CEODaniel O'Day
Employees17,000
HeadquartersFoster City, CA, US
IPO date1992-01-22
Websitewww.gilead.com

What you can see for GILD on Tickr

Live GILD price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the GILD report.

Rankings

Largest Healthcare companiesLargest companies by market cap

GILD peers

AMGNBMYBSXDHRGSKMRKNVOPFE

FAQ

What is the ticker symbol for Gilead Sciences, Inc.?

The ticker symbol for Gilead Sciences, Inc. is GILD, listed on the NASDAQ Global Select.

What is GILD?

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it…

HomeExploreMarketLists
All pages